At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NRXS Neuraxis, Inc.
Not Yet Opened 03-27 16:00:00 EDT
2.13
-0.02
-0.87%
盘后2.13
+0.000.00%
19:43 EDT
| High2.18 | Low2.04 | Vol2.06K |
| Open2.04 | D1 Closing2.15 | Amplitude6.51% |
| Mkt Cap15.38M | Tradable Cap7.11M | Total Shares7.22M |
| T/O4.33K | T/O Rate0.06% | Tradable Shares3.34M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth
Zacks · 03-24
NeurAxis, Inc. Reports Strong Q4 Growth Amid Challenges
TIPRANKS · 03-22
NeurAxis, Inc. Reports Strong Q4 2024 Results
TIPRANKS · 03-21
Neuraxis reports Q4 revenue $761,000 vs. $531,000 last year
TIPRANKS · 03-20
Neuraxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
THOMSON REUTERS · 03-20
Press Release: NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
Dow Jones · 03-20
Neuraxis Q4 EPS $(0.23) Up From $(0.85) YoY, Sales $761.16K Up From $531.46K YoY
Benzinga · 03-20
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
GlobeNewswire · 01-21
Neuraxis issues letter to shareholders
TIPRANKS · 01-13
Press Release: NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year
Dow Jones · 01-08
Neuraxis files $25M mixed securities shelf
TIPRANKS · 2024-12-13
Neuraxis files to sell 6.57M shares of common stock for holders
TIPRANKS · 2024-12-13
Neuraxis Inc Files for Mixed Shelf of up to $25 Mln – SEC Filing
THOMSON REUTERS · 2024-12-13
Neuraxis Inc: Selling Stockholders May Offer and Sell up to 6.6 Mln Shares of Common Stock
THOMSON REUTERS · 2024-12-13
Neuraxis Inc. Announces FDA 510(K) Clearance of Red for Testing and Evaluation of Patients With Chronic Constipation
THOMSON REUTERS · 2024-12-10
Neuraxis Inc: Will Begin Process of Commercially Marketing Red and Expects Initial Revenues in 1Q25
THOMSON REUTERS · 2024-12-10
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
GlobeNewswire · 2024-12-10
NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation
BRIEF-Rosalind Advisors, Inc. Reports 9.9% Stake In Neuraxis Inc As Of November 12- SEC Filing
Reuters · 2024-12-02
Rosalind Advisors, Inc. Reports 9.9% Stake in Neuraxis Inc as of November 12- SEC Filing
THOMSON REUTERS · 2024-12-02
Rosalind Advisors: on Nov 19, Appointed Aharon to Neuraxis Board, Effective Jan 1, 2025
THOMSON REUTERS · 2024-12-02
Introduction
Company Name.
Neuraxis, Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. NeurAxis, Inc. was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is based in Versailles, Indiana.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App